The Sponsor needed to find a way of dealing with unsolicited patient requests for its phase 2 study drug.
The Sponsor needed to find a cost- and time-effective alternative to an OLEX study for providing access to the study drug, post-phase 3 clinical trials.
The Sponsor needed to end a long standing OLEX study, that was set up after its phase 3 trials had ended.
This website is using cookies, by continuting to access this website you are agreeing to their use. Learn more about cookies.